The efficacy and safety of ciprofol use for the induction of general anesthesia in patients undergoing gynecological surgery: a prospective randomized controlled study

Table 3 Adverse event incidence during the peri-anesthetization period

Variable	Ciprofol group (n = 60)	Propofol group (n = 60)	P-value
Intubation response, n(%)
swallowing,	0	3(5%)
cough	0	1(1.67%)
body moving	0	2(3.33%)
tears	0	1(1.67%)
hypertension	4(6.67%)	2(3.33%)
hypotension	5(8.33%)	16(26.67%)
bradycardia	2(3.33%)	1(1.67%)
tachycardia	1(1.67%)	3(5%)
total	12(20%)	29(48.33%)	0.0019
Injection-site pain, n(%)	10(16.7%)	35(58.3%)	< 0.001

Hypertension, hypotension, bradycardia and tachycardia were defined as occurred within 10 min after administration of the study drug were recorded; hypertension: an increase of 20% than baseline value; hypotension: an decrease of 20% than baseline; bradycardia: heart rates less than 55 beats/min; tachycardia: heart rates more than 100 beats/min; Injection-site pain: with a withdrawal response or a numeric rating scale value ≥ 3

ISSN: 1471-2253